The platform for proteins by design, not by evolution.
Miniproteins are the ideal modality for modern biologics
A closed-loop engine for de novo protein design
Design
Generative AI creates miniproteins de novo, specifying stability, affinity, and pharmacology from the start. Every molecule is purpose-built.
Make
Automated technologies bring designs to life, generating thousands of candidates in parallel with speed and scale.
Test
Each candidate is validated in the lab for structure, biophysics, and function, turning digital predictions into proven drug-like data.
Optimize & Learn
Our AI-directed mutagenesis engine (AWESSM) feeds experimental results back into the models, systematically refining designs into novel, patentable molecules.
Evidence at industrial scale
150+ targets explored. Multiple in vivo proofs-of-concept achieved.
Strategic collaboration with BMS A multi‑year, $400M discovery partnership for 2 undisclosed miniprotein targets
Anti-inflammatory program
Equivalent efficacy to approved antibody
Immune activator
Tumor-killing validated in animal models
GLP-1 agonist
Superior activity to semaglutide in vivo
